Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study With Lurasidone Injectable Suspension to Evaluate Safety, Tolerability and Pharmacokinetics in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
In Long BeachA Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveResearchers compared JNJ-31001074 1 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 10 mg/d, Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockA Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveResearchers compared dasotraline 4mg, dasotraline 6mg and placebo, tracking side effects to assess safety and tolerability in adults with binge eating.
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixResearchers compared ABT-126 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AnaheimA Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
Read the official source — NCT00396565Researchers compared ER OROS paliperidone, placebo and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Aizu-WakamatsuA Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including AntwerpResearchers compared RE03 and placebo, tracking side effects to assess safety in people with PTSD.
This study has finished and is no longer accepting participants.
In ZurichA Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
This study has finished and is no longer accepting participants.
Multiple locations, including Costa MesaA Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets
This study has finished and is no longer accepting participants.
Multiple locations, including BaodingA Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression
This study has finished and is no longer accepting participants.
Multiple locations, including ChandlerWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.